台灣臨床試驗主持人資料庫|TPIDB

2020-03-13 - 2024-02-15

Phase I/II

Completed

An open phase 1b/2 trial to evaluate the pharmacokinetics, safety, efficacy and pharmacodynamics of PF-06801591 (PD-1 inhibitor) among participants in advanced malignancies

Condition/Disease

NSCLC
Test Drug

PF-06801591

Participate Sites
4Sites

Recruiting2Sites

Terminated2Sites

洪仁宇

Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital

Division of Thoracic Medicine

2019-01-01 - 2027-05-27

Phase III

Active

A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Subjects with Metastatic Prostate Cancer

Condition/Disease

Metastatic prostate cancer
Test Drug

Niraparib

Participate Sites
9Sites

Recruiting8Sites

Terminated1Sites

吳文正

Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital

Division of Urology

2018-10-30 - 2022-12-31

Phase III

Completed

A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations

Condition/Disease

Urothelial Cancer
Test Drug

Erdafitinib

Participate Sites
12Sites

Recruiting2Sites

Terminated10Sites

吳文正

Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital

Division of Urology

2014-02-01 - 2016-01-31

Phase III

Acute Stroke Or Transient IsChemic Attack TReated with Aspirin or Ticagrelor and Patient OutcomES

Condition/Disease

Patients with an acute cerebral ischemic event (minor stroke/high-risk TIA) and high risk of subsequent ischemic stroke, who could be randomised within 24 hours of symptom onset
Test Drug

Ticagrelor

Participate Sites
11Sites

Terminated10Sites

Study ended1Sites

林瑞泰

Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital

Division of Neurology

2008-12-01 - 2011-11-30

Phase III

A randomised, double-blind, parallel-group placebo-controlled phase Ill study to evaluate the efficacy and safety of desmoteplase in subjects with acute ischemic stroke

Condition/Disease

Ischemic stroke
Test Drug

Desmoteplase

Participate Sites
6Sites

Terminated6Sites

劉景寬

Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital

Division of Neurology

2019-06-01 - 2024-07-31

Phase III

A Phase 3, Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Lenvatinib (E7080/MK-7902) Versus Pembrolizumab and Placebo as First Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma in Cisplatin-ineligible Participants Whose Tumors Express PD-L1, and in Participants Ineligible for Any Platinum-containing Chemotherapy Regardless of PD-L1 Expression (LEAP-011)

Condition/Disease

Locally Advanced or Metastatic Urothelial Carcinoma
Test Drug

Lenvatinib Pembrolizumab

Participate Sites
7Sites

Recruiting7Sites

吳文正

Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital

Division of Urology

2019-10-01 - 2021-06-30

Phase II

A Phase IIa, Double-Blind, Single Dose, Randomized, Placebo-ControlledStudy to Evaluate the Safety, Tolerability, and Potential Efficacy of LT3001 Drug Product in Subjects with Acute Ischemic Stroke (AIS)

Condition/Disease

Acute Ischemic Stroke
Test Drug

LT3001 drug product

Participate Sites
6Sites

Recruiting4Sites

Study ended2Sites

趙雅琴

Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital

Division of Neurology

2015-04-01 - 2018-12-31

Phase III

Randomized, double-blind, Evaluation in secondary Stroke Prevention comparing the EfficaCy and safety of the oral Thrombin inhibitor dabigatran etexilate (110 or 150 mg, oral, b.i.d) versus acetylsalicytic acid (100mg oral q.d.) in patients with Embolic Stroke of Undetermined Source (RE-SPECT ESUS).

Condition/Disease

Embolic stroke of undetermined source
Test Drug

Pradaxa/Placebo

Participate Sites
14Sites

Terminated13Sites

Study ended1Sites

林秀芬

Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital

Division of Neurology

2008-12-15 - 2010-12-31

Phase III

Open-Label Extension Study of 23 mg Donepezil SR in Patients with Moderate to Severe Alzheimer’s Disease.

Condition/Disease

Alzheimer's disease
Test Drug

Donepezil SR 23mg

Participate Sites
3Sites

Terminated3Sites

劉景寬

Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital

Division of Neurology

2007-11-01 - 2009-12-31

Phase III

Double-Blind, Parallel-Group Comparison of 23 mg Donepezil Sustained Release to 10 mg Donepezil Immediate Release in Patients with Moderate to Severe Alzheimer’s Disease

Condition/Disease

Alzheimer's disease
Test Drug

Donepezil

Participate Sites
4Sites

Terminated4Sites

劉景寬

Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital

Division of Neurology

Search Result

List